Search results
Results from the WOW.Com Content Network
The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase ...
2 Side effects. 3 Interactions. ... is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. [4] ... Immune system changes (e.g. Immune ...
Emtricitabine/tenofovir is also used for HIV post-exposure prophylaxis. People who start taking emtricitabine/tenofovir see HIV reduction benefits up to 72 hours after starting, but the medicine must be taken for thirty days after a high-risk sexual event to ensure HIV transmission levels are optimally reduced. [21] [22]
IRIS may occur which is when the immune system initially improves, but then deteriorates as a previously ignored infection becomes active. Other serious side effects include: [12] Increased risk of heart attack; Lactic acidosis; Severe hepatomegaly; Lipoatrophy; Neutropenia; Anemia; Hypersensitivity reactions
Fostemsavir may cause a serious condition called immune reconstitution syndrome, similar to other approved drugs for treatment of HIV-1 infection. [8] This condition can happen at the beginning of HIV-1 treatment when the immune system may get stronger and begin to fight infections that have been hidden in the body for a long time. [8]
Combination therapy for HIV, often called highly active antiretroviral therapy (HAART), is composed of two or more types of antiretroviral drugs. Combination therapy decreases the likelihood that drug resistance will occur, because it is unlikely that the HIV-1 strains will be able to mutate enough to become resistant to all drugs being used in ...
It works by inhibiting the enzyme reverse transcriptase that HIV uses to make DNA and therefore decreases replication of the virus. [6] Zidovudine was first described in 1964. [7] It was resynthesized from a public-domain formula by Burroughs Wellcome. [8] It was approved in the United States in 1987 and was the first treatment for HIV.
Common side effects include headache, feeling tired, nausea, diarrhea, and fever. [3] Severe side effects may include bone marrow suppression, muscle damage, worsening of hepatitis B if previously infected, high blood lactate and liver enlargement. [2] [4] It may be part of a recommended treatment during pregnancy. [2]